CCT129202 Chemical Structure
VX-680 (MK-0457, Tozasertib) is the inhibitor of Aurora-A,-B,-C kinases with apparent inhibition constant values of 0.6,18,4.6 nM respectively.
MLN8054 is an Aurora inhibitor, Aurora A (IC50 = 0.004 uM) over Aurora B (IC50 = 0.172 uM).
ZM-447439 is a poten, selective ATP-competitive Aurora B kinase inhibitor with an IC50 of 50 nM, 1 μM and 250 nM for Aurora B, A and C, respectively.
Danusertib (PHA-739358) is a pyrrolo-pyrazole and small molecule aurora kinases and Bcr-Abl kinase inhibitor for aurora A, B, and C with IC50 of 13 nM, 79 nM, and 61 nM, respectively.
MLN8237 (Alisertib) is a selective Aurora kinase A inhibitor with a median IC50 of 61 nM.
AT9283 is a small molecule a multi-targeted c-ABL, JAK2, Aurora A and B inhibitor with IC50 of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.
AZD1152-HQPA (Barasertib) is a highly potent and selective inhibitor of Aurora B (Ki, 0.36 nM)
SNS-314 Mesylate is a potent and selective Aurora kinase inhibitor with IC50 of 9, 31, and 3.4 nM for Aurora kinases A, B, and C, respectively.
CYC116 is an Aurora kinase/VEGFR2 inhibitor
ENMD-2076 is a antiangiogenic and Aurora kinase inhibitor with IC50 of 3, 13, 350, 23, 40, 93 and 120 nM for Flt-3, AurA, AurB, Src, KDR/VEGFR2 and FGFR1.
CCT129202 is a Aurora kinase inhibitor with IC50 of 0.042 ± 0.022, 0.198 ± 0.05, and 0.227 ± 0.064 μmol/L for Aurora A, Aurora B, and Aurora C, respectively.It showed high selectivity for the Aurora kinases over a panel of other kinases tested and inhibits proliferation in multiple cultured human tumor cell lines. CCT129202 causes the accumulation of human tumor cells with ≥4N DNA content, leading to apoptosis. The results showed that the CCT129202 is an ATP-competitive inhibitor of recombinant Aurora A kinase with a Ki of 49.8 nmol/L. [1][2]
| Molecular Weight (WM): | 497.02 |
|---|---|
| Formula: | C23H25ClN8OS |
| CAS No.: | 942947-93-5 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥3mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
A collection of 864 bioactive compounds
A collection of 481 inhibitors
A collection of 194 kinase inhibitors
A collection of 85 tyrosine kinase inhibitors.
A collection of 426 FDA approved drugs
A collection of 139 natural products
A collection of 40 chemotherapeutic agents
A unique collection of 17 small molecule modulators
A unique collection of 47 small molecule inhibitors
A unique collection of 63 GPCR small molecules

T47D Breast cancer cells were pretreated with p-Aurora, Aurora and then treated with the indicated concentrations of CCT129202.
|
T47D Breast cancer cells were pretreated with p-Aurora, Aurora and then treated with the indicated concentrations of CCT129202.
Data independently produced by Dr Zhang of Tianjin Medical University CCT129202 purchased from Selleck
Keywords:buy CCT129202 | CCT129202 supplier | purchase CCT129202 | CCT129202 cost | CCT129202 manufacturer | order CCT129202 | CCT129202 distributor